We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+3.58%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$69.4B
AUM Growth
+$3.54B
Cap. Flow
+$1.44B
Cap. Flow %
2.08%
Top 10 Hldgs %
21.44%
Holding
3,843
New
225
Increased
1,690
Reduced
1,576
Closed
217

Sector Composition

Rank Sector Weight
1 Technology 10.52%
2 Financials 9.29%
3 Healthcare 8.12%
4 Industrials 6.67%
5 Consumer Discretionary 5.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RY icon
376
Royal Bank of Canada
RY
$293B
$32.6M 0.05%
411,767
-7,304
-2% -$571K
EPR icon
377
EPR Properties
EPR
$4.77B
$32.5M 0.05%
435,103
+292,489
+205% +$22.8M
PRFZ icon
378
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
$2.89B
$32.4M 0.05%
1,267,135
+134,180
+12% +$3.43M
NOC icon
379
Northrop Grumman
NOC
$81.2B
$32.2M 0.05%
99,593
+3,853
+4% +$1.15M
ACWX icon
380
iShares MSCI ACWI ex US ETF
ACWX
$11.8B
$32.1M 0.05%
686,594
-145,127
-17% -$6.74M
BSV icon
381
Vanguard Short-Term Bond ETF
BSV
$44.6B
$32M 0.05%
396,901
+176,574
+80% +$14.1M
EFAV icon
382
iShares MSCI EAFE Min Vol Factor ETF
EFAV
$5.51B
$31.9M 0.05%
439,091
+19,888
+5% +$1.43M
FIS icon
383
Fidelity National Information Services
FIS
$22.1B
$31.8M 0.05%
259,540
+18,121
+8% +$2.13M
FDS icon
384
Factset
FDS
$10.2B
$31.7M 0.05%
110,453
-6,855
-6% -$1.9M
BSX icon
385
Boston Scientific
BSX
$71.5B
$31.6M 0.05%
735,750
+40,874
+6% +$1.57M
ET icon
386
Energy Transfer Partners
ET
$69.3B
$31.6M 0.05%
2,242,618
+244,026
+12% +$3.61M
WOLF icon
387
Wolfspeed
WOLF
$1.71B
$31.5M 0.05%
560,932
-24,474
-4% -$1.5M
SIX
388
DELISTED
Six Flags Entertainment Corp.
SIX
$31.5M 0.05%
633,566
+374,345
+144% +$19.3M
RELX icon
389
RELX
RELX
$62B
$31.4M 0.05%
1,288,344
-171,031
-12% -$3.93M
SHW icon
390
Sherwin-Williams
SHW
$89.8B
$31.4M 0.05%
205,599
+11,286
+6% +$1.69M
WDC icon
391
Western Digital
WDC
$150B
$31.4M 0.05%
873,120
-31,322
-3% -$1.07M
JKHY icon
392
Jack Henry & Associates
JKHY
$11.1B
$31.3M 0.05%
234,070
+12,400
+6% +$1.71M
SPLK
393
DELISTED
Splunk Inc
SPLK
$31.2M 0.05%
248,281
+7,682
+3% +$976K
IVZ icon
394
Invesco
IVZ
$13.9B
$31.2M 0.04%
1,523,787
+558,185
+58% +$11.6M
MGK icon
395
Vanguard Morningstar Mega Cap Growth ETF
MGK
$34.2B
$31M 0.04%
1,197,000
+36,350
+3% +$925K
RPV icon
396
Invesco S&P 500 Pure Value ETF
RPV
$1.68B
$30.9M 0.04%
475,551
+19,871
+4% +$1.27M
SCHW
397
Charles Schwab
SCHW
$187B
$30.7M 0.04%
763,987
+114,926
+18% +$5.01M
AJG icon
398
Arthur J. Gallagher & Co
AJG
$63.6B
$30.6M 0.04%
349,319
+10,057
+3% +$839K
ELV icon
399
Elevance Health
ELV
$85.5B
$30.4M 0.04%
107,805
+16,233
+18% +$4.43M
ROST icon
400
Ross Stores
ROST
$81.9B
$30.4M 0.04%
306,739
-654
-0.2% -$63.7K

Similar funds

Raymond James & Associates's Q2 2019 Portfolio in Review

As of Q2 2019, Raymond James & Associates held 3,843 positions worth $69.4B, up 5.4% from $65.8B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Raymond James & Associates's Q2 2019 filing shows 225 new, 1,690 increased, 1,576 reduced and 217 closed positions. Its largest new stake was Dow Inc: 851,378 shares worth $42M. The largest sale was AbbVie, an estimated $134M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q2 2019 buy was Dow Inc: 851,378 shares worth $42M.
  • Raymond James & Associates added most to Medtronic in Q2 2019, an estimated $157M increase.
  • Raymond James & Associates's biggest Q2 2019 reduction was AbbVie, cutting an estimated $134M.
  • Raymond James & Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $5.43M.
  • Raymond James & Associates's ten largest holdings make up 21% of its $69.4B portfolio in Q2 2019.
  • Raymond James & Associates opened 225 new positions and closed 217 in Q2 2019.
  • Raymond James & Associates's portfolio value rose 5.4% quarter-over-quarter to $69.4B.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.